Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23084701 | 1.00 | BACE1 (0.38) | BACE1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21122067 | 0.84 | BACE1 (0.41) | BACE1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29868015 | 0.81 | MEN1 (0.38) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL23084702 | 0.81 | MEN1 (0.38) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL30270924 | 0.79 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31172125 | 0.78 | CASP3 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22636487 | 0.78 | CASP3 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23698605 | 0.77 | HTT (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23698705 | 0.76 | ALDH1A1 (0.35) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| SCHEMBL23084799 | 0.75 | POLB (0.38) | CASP3SENP8SENP7SENP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | BACE1 2491/4885CHRM2 1793/4885CHRM4 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.